Everest medicines expands strategic investment in i-mab

- everest will invest us$30.9 million (equivalent to approximately hk$242.6 million) in cash in i-mab. inclusive of i-mab shares already held by everest, the pro forma ownership will be 16.1%.

EG Ratings Summary

EG Quant Ranking